Changing Healthcare Worldwide

Making medical advancements everyday

In the early 1990’s, Kenneth B. Kirby began researching ways to improve the safety and efficiency of transdermal drug delivery. He began by investigating which compounds could transmigrate the skin readily and rapidly, without the need to overcome the natural protective barriers of the stratum corneum, the outermost layer of human skin. His research led to the formation of Transdermal Delivery Solutions Corporation (TDSC). 

The company was awarded the first patent for its spray-on Transdermal Delivery System (TDS) in 2002. Since then, TDSC has been working with the research divisions of several pharmaceutical companies to explore and develop TDS versions of their products. 

In 2012, TDSC announced it was in the final stages of developing its first product, Testagen™, a spray-on treatment for low testosterone levels in men. Testagen™ has been under evaluation for 10 years and has undergone two human trials. Continuing clinical trials are expected to begin in 2013. 

Research is currently underway into spray-on delivery of other compounds, including pain management drugs, antihistamines, and other pharmaceuticals.